03.09.2026journal-article
Asian Journal of Oncology
Integrating molecular engineering and artificial intelligence to overcome clinical and manufacturing challenges in CAR-T therapy
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in addressing hematological malignancies. However, its broader clinical application in other cancer types is still limited by key challenges like antigen escape, on-target/off-tumor toxicity, reduced efficacy for solid malignancies, and large variability in the production process for CAR T-cells. Traditional optimization approaches are increasingly insufficient to address these complex challenges. Notably, current studies do not ful …